Neurocrine Biosciences, Inc. (NBIX)
169.40
-5.01
(-2.87%)
USD |
NASDAQ |
Nov 12, 16:00
169.47
+0.07
(+0.04%)
After-Hours: 20:00
Neurocrine Biosciences Enterprise Value : 16.81B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 16.81B |
| November 11, 2026 | 17.32B |
| November 10, 2026 | 16.79B |
| November 09, 2026 | 16.76B |
| November 06, 2026 | 16.33B |
| November 05, 2026 | 15.84B |
| November 04, 2026 | 16.48B |
| November 03, 2026 | 16.35B |
| November 02, 2026 | 14.38B |
| October 30, 2026 | 14.45B |
| October 29, 2026 | 14.48B |
| October 28, 2026 | 14.40B |
| October 27, 2026 | 14.44B |
| October 26, 2026 | 14.43B |
| October 23, 2026 | 14.11B |
| October 22, 2026 | 14.17B |
| October 21, 2026 | 13.97B |
| October 20, 2026 | 14.04B |
| October 19, 2026 | 13.53B |
| October 16, 2026 | 13.40B |
| October 15, 2026 | 13.53B |
| October 14, 2026 | 13.42B |
| October 13, 2026 | 13.34B |
| October 12, 2026 | 13.98B |
| October 09, 2026 | 14.08B |
| Date | Value |
|---|---|
| October 08, 2026 | 13.96B |
| October 07, 2026 | 14.19B |
| October 06, 2026 | 14.39B |
| October 05, 2026 | 14.26B |
| October 02, 2026 | 14.16B |
| October 01, 2026 | 13.91B |
| September 30, 2026 | 14.02B |
| September 29, 2026 | 14.07B |
| September 28, 2026 | 14.28B |
| September 25, 2026 | 14.07B |
| September 24, 2026 | 14.13B |
| September 23, 2026 | 14.18B |
| September 22, 2026 | 14.46B |
| September 21, 2026 | 14.64B |
| September 18, 2026 | 14.87B |
| September 17, 2026 | 15.44B |
| September 16, 2026 | 15.20B |
| September 15, 2026 | 15.25B |
| September 14, 2026 | 15.99B |
| September 11, 2026 | 15.88B |
| September 10, 2026 | 15.92B |
| September 09, 2026 | 15.77B |
| September 08, 2026 | 15.77B |
| September 04, 2026 | 15.83B |
| September 03, 2026 | 16.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 293.45B |
| Halozyme Therapeutics, Inc. | 13.65B |
| BioCryst Pharmaceuticals, Inc. | 2.420B |
| Iovance Biotherapeutics, Inc. | 3.198B |
| Precigen, Inc. | 1.723B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 206.50M |
| Revenue (Quarterly) | 1.123B |
| Total Expenses (Quarterly) | 916.20M |
| EPS Diluted (Quarterly) | 1.963 |
| Gross Profit Margin (Quarterly) | 94.51% |
| Profit Margin (Quarterly) | 18.39% |
| Earnings Yield | 3.98% |
| Operating Earnings Yield | 5.16% |
| Normalized Earnings Yield | 4.275 |